Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins against SARS-CoV-2

Burnouf, Thierry and Gathof, Brigit and Grubovik Rastvorceva, Rada (2022) Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins against SARS-CoV-2. Transfusion Medical Reviews. (In Press)

	Text pii/S0887796322000219 Download (13kB)
	Text Hyperimmune immunoglobulins - Transfusion Medical Reviews 1-s2.0-S0887796322000219-main.pdf Download (1MB)

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the potential therapeutic value of early passive polyclonal immunotherapy using high-titer convalescent plasma (CCP). Human polyclonal hyperimmune immunoglobulin (HIG) has several advantages over CCP. Unlike CCP, HIG can provide standardized and controlled antibody content. It is also subjected to robust pathogen reduction rendering it virally safe and is purified by technologies demonstrated to preserve immunoglobulin neutralization capacity and Fc fragment integrity. This document provides an overview of current practices and guidance for the collection and testing of plasma rich in antibodies against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and its industrial fractionation for the manufacture of quality-assured and safe HIG. Considerations are also given to the production of HIG preparations in low- and middle-income countries.

Item Type:	Article
Impact Factor Value:	4.724
Subjects:	Medical and Health Sciences > Clinical medicine
Divisions:	Faculty of Medical Science
Depositing User:	Rada Grubovik Rastvorceva
Date Deposited:	15 Aug 2022 09:26
Last Modified:	15 Aug 2022 09:30
URI:	https://eprints.ugd.edu.mk/id/eprint/30007

Actions (login required)

View Item